November 6, 2025
FOCUS on New Drug Approvals. The FDA just announced approval of Revumenib, a first-in-class oral menin inhibitor, for the treatment of adults and children with relapsed […]
October 29, 2025
FOCUS on SIRT6. Sirtuin 6 (SIRT6) is an NAD-dependent histone deacetylase shown to function as a tumor suppressor in several cancer types. However, the therapeutic potential […]
November 26, 2024
Focus on Drug Approvals. The FDA has approved Syndax Pharmaceuticals’ Revumenib (SNDX-5613, inhibitor of menin-KMT2A interaction) for relapsed or refractory acute leukemia with lysine methyltransferase 2A […]
March 29, 2024
Last week the FDA approved Italfarmaco’s givinostat (ITF2357) for Duchenne muscular dystrophy. Givinostat is a novel histone deacetylase (HDAC) inhibitor and was approved for DMD patients […]
September 8, 2022
Robert Prior and coworkers report in a recent issue of Molecular Neurobiology that inhibition of HDAC3 with RGFP966, a highly selective HDAC3 inhibitor, stimulates myelination in […]
August 25, 2022
In a recent paper in Cell Research, Li and coworkers explored the nuclear function of RIPK1 and demonstrated that RIPK1 phosphorylates a key component of the […]
March 3, 2022
NSD2 (nuclear receptor-binding SET domain-containing 2) is a methyltransferase that specifically targets histone H3 at Lysine 36 (making it a H3K36me2 in chromatin remodeling nomenclature). It […]